BACKGROUND: Vel is a high frequency blood group antigen and its alloantibody is involved in haemolytic transfusion reactions. After elucidation of the molecular basis of the Vel-negative phenotype defined by a 17-base pair deletion in SMIM1, genotyping has been the technique of choice to identify the Vel-negative phenotype, and molecular investigations have contributed to explain Vel expression variability. The present study was aimed at screening for Vel negative blood donors and characterising the genetic changes found in Brazilian donors with altered Vel expression. MATERIALS AND METHODS: Molecular screening for the SMIM1*64_80del allele was performed in 1,595 blood donor samples using a SNaPshot protocol previously standardised in our laboratory. Four hundred donor samples were also submitted to serological screening using a polyclonal anti-Vel from our inventory. Samples with variability in antigen strength were selected for SMIM1 sequencing. RESULTS: No homozygous SMIM1*64_80del allele was found and the SMIM1*64_80del allele frequency was 1.01%. Different patterns of reactivity were observed in serological testing varying from negative to 3+. Through sequencing analysis we highlighted two polymorphisms: rs1175550 and rs6673829. The minor G allele of rs1175550 was found in 16/20 samples reacting 3+, while the major A allele was found in 21/23 samples reacting 2+. Regarding rs6673829, the minor A allele was present in 14/23 and 3/20 samples reacting 2+ and 3+ respectively. DISCUSSION: We included molecular VEL screening in a previously standardised SNaPshot protocol, which besides enabling detection of Vel-negative donors, also searches for eight other rare blood types. Additionally, the present study demonstrated that although the SMIM1*64_80del allele is responsible for some variation of Vel phenotype in this donor population, Vel expression is also controlled by molecular changes in SMIM1 intron 2.
BACKGROUND:Vel is a high frequency blood group antigen and its alloantibody is involved in haemolytic transfusion reactions. After elucidation of the molecular basis of the Vel-negative phenotype defined by a 17-base pair deletion in SMIM1, genotyping has been the technique of choice to identify the Vel-negative phenotype, and molecular investigations have contributed to explain Vel expression variability. The present study was aimed at screening for Vel negative blood donors and characterising the genetic changes found in Brazilian donors with altered Vel expression. MATERIALS AND METHODS: Molecular screening for the SMIM1*64_80del allele was performed in 1,595 blood donor samples using a SNaPshot protocol previously standardised in our laboratory. Four hundred donor samples were also submitted to serological screening using a polyclonal anti-Vel from our inventory. Samples with variability in antigen strength were selected for SMIM1 sequencing. RESULTS: No homozygous SMIM1*64_80del allele was found and the SMIM1*64_80del allele frequency was 1.01%. Different patterns of reactivity were observed in serological testing varying from negative to 3+. Through sequencing analysis we highlighted two polymorphisms: rs1175550 and rs6673829. The minor G allele of rs1175550 was found in 16/20 samples reacting 3+, while the major A allele was found in 21/23 samples reacting 2+. Regarding rs6673829, the minor A allele was present in 14/23 and 3/20 samples reacting 2+ and 3+ respectively. DISCUSSION: We included molecular VEL screening in a previously standardised SNaPshot protocol, which besides enabling detection of Vel-negative donors, also searches for eight other rare blood types. Additionally, the present study demonstrated that although the SMIM1*64_80del allele is responsible for some variation of Vel phenotype in this donor population, Vel expression is also controlled by molecular changes in SMIM1 intron 2.
Authors: Lonneke Haer-Wigman; Tamara C Stegmann; Shabnam Solati; Aïcha Ait Soussan; Erik Beckers; Pim van der Harst; Marga van Hulst-Sundermeijer; Peter Ligthart; Dick van Rhenen; Hein Schepers; Masja de Haas; C Ellen van der Schoot Journal: Transfusion Date: 2015-02-03 Impact factor: 3.157
Authors: D C Costa; M Dezan; T Santos; A A Schinaider; E J Schörner; J E Levi; M C Santos-Silva Journal: Transfus Med Date: 2016-06-21 Impact factor: 2.019
Authors: Marcia R Dezan; Carla L Dinardo; Silvia R A Bosi; Sileni Vega; Nanci A Salles; Alfredo Mendrone-Júnior; José E Levi Journal: Transfusion Date: 2016-04-05 Impact factor: 3.157
Authors: Jill R Storry; Magnus Jöud; Mikael Kronborg Christophersen; Britt Thuresson; Bo Åkerström; Birgitta Nilsson Sojka; Björn Nilsson; Martin L Olsson Journal: Nat Genet Date: 2013-04-07 Impact factor: 38.330
Authors: Ana Cvejic; Lonneke Haer-Wigman; Jonathan C Stephens; Pim van der Harst; C Ellen van der Schoot; Willem H Ouwehand; Cornelis A Albers; Myrto Kostadima; Peter A Smethurst; Mattia Frontini; Emile van den Akker; Paul Bertone; Ewa Bielczyk-Maczyńska; Samantha Farrow; Rudolf Sn Fehrmann; Alan Gray; Masja de Haas; Vincent G Haver; Gregory Jordan; Juha Karjalainen; Hindrik Hd Kerstens; Graham Kiddle; Heather Lloyd-Jones; Malcolm Needs; Joyce Poole; Aicha Ait Soussan; Augusto Rendon; Klaus Rieneck; Jennifer G Sambrook; Hein Schepers; Herman H W Silljé; Botond Sipos; Dorine Swinkels; Asif U Tamuri; Niek Verweij; Nicholas A Watkins; Harm-Jan Westra; Derek Stemple; Lude Franke; Nicole Soranzo; Hendrik G Stunnenberg; Nick Goldman Journal: Nat Genet Date: 2013-04-07 Impact factor: 38.330